| Prevention of HIV-1 infection with early antiretroviral therapy MS Cohen, YQ Chen, M McCauley, T Gamble, MC Hosseinipour, ... New England journal of medicine 365 (6), 493-505, 2011 | 8828 | 2011 |
| Timing of antiretroviral therapy for HIV-1 infection and tuberculosis DV Havlir, MA Kendall, P Ive, J Kumwenda, S Swindells, SS Qasba, ... New England Journal of Medicine 365 (16), 1482-1491, 2011 | 730 | 2011 |
| Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial AR Zolopa, J Andersen, L Komarow, I Sanne, A Sanchez, E Hogg, ... PloS one 4 (5), e5575, 2009 | 723 | 2009 |
| Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial B Grinsztejn, MC Hosseinipour, HJ Ribaudo, S Swindells, J Eron, ... The Lancet infectious diseases 14 (4), 281-290, 2014 | 638 | 2014 |
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ... The Lancet infectious diseases 17 (1), 39-49, 2017 | 386 | 2017 |
| Four-month rifapentine regimens with or without moxifloxacin for tuberculosis SE Dorman, P Nahid, EV Kurbatova, PPJ Phillips, K Bryant, KE Dooley, ... New England Journal of Medicine 384 (18), 1705-1718, 2021 | 376 | 2021 |
| Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects I Sanne, H Mommeja-Marin, J Hinkle, JA Bartlett, MM Lederman, ... The Journal of infectious diseases 191 (6), 825-829, 2005 | 349 | 2005 |
| Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial S Rosen, M Maskew, MP Fox, C Nyoni, C Mongwenyana, G Malete, ... PLoS medicine 13 (5), e1002015, 2016 | 313 | 2016 |
| Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial I Sanne, C Orrell, MP Fox, F Conradie, P Ive, J Zeinecker, M Cornell, ... The Lancet 376 (9734), 33-40, 2010 | 306 | 2010 |
| Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? AV Rie, L Page-Shipp, L Scott, I Sanne, W Stevens Expert review of molecular diagnostics 10 (7), 937-946, 2010 | 304 | 2010 |
| Opportunities and challenges for HIV care in overlapping HIV and TB epidemics DV Havlir, H Getahun, I Sanne, P Nunn Jama 300 (4), 423-430, 2008 | 252 | 2008 |
| Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study LE Scott, K McCarthy, N Gous, M Nduna, A Van Rie, I Sanne, WF Venter, ... PLoS medicine 8 (7), e1001061, 2011 | 236 | 2011 |
| Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ... The Lancet Respiratory Medicine 1 (10), 786-792, 2013 | 235 | 2013 |
| A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS JA Vazquez, DJ Skiest, L Nieto, R Northland, I Sanne, J Gogate, ... Clinical infectious diseases 42 (8), 1179-1186, 2006 | 222 | 2006 |
| The impact and cost of scaling up GeneXpert MTB/RIF in South Africa G Meyer-Rath, K Schnippel, L Long, W MacLeod, I Sanne, W Stevens, ... PloS one 7 (5), e36966, 2012 | 203 | 2012 |
| Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection PM Grant, L Komarow, J Andersen, I Sereti, S Pahwa, MM Lederman, ... PloS one 5 (7), e11416, 2010 | 198 | 2010 |
| Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration DW Haas, JA Bartlett, JW Andersen, I Sanne, GR Wilkinson, J Hinkle, ... Clinical infectious diseases 43 (6), 783-786, 2006 | 188 | 2006 |
| Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies A Van Rie, D Westreich, I Sanne JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (4), 349-355, 2011 | 169 | 2011 |
| Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action BJ Marais, MC Raviglione, PR Donald, AD Harries, AL Kritski, ... The Lancet 375 (9732), 2179-2191, 2010 | 169 | 2010 |
| Cost-effectiveness of HIV treatment as prevention in serodiscordant couples RP Walensky, EL Ross, N Kumarasamy, R Wood, F Noubary, AD Paltiel, ... New England Journal of Medicine 369 (18), 1715-1725, 2013 | 161 | 2013 |
